Androgen deprivation therapy and prostate cancer duration

Journal of Clinical Oncology

Volumn 27, Issue 34, 2009, Pages

  Williams, Scott G ^a   Pickles, Tom ^b   Buyyounouski, Mark K ^c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; DISEASE DURATION; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION; MALE; NOTE; PROSTATE TUMOR;

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 73349143969     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.4137     Document Type: Letter

References (1)

1. Souhami L, Bae K, Pilepich M, et al: Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: A secondary analysis of RTOG 85-31. J Clin Oncol 27:2137-2143, 2009